Search - tctmd.com

Displaying 961 - 980 of 1458

Sort: Relevancy | Date

Presentation TVT 2014

Why Cerebral Protection after TAVR Will Become the Standard of Care

Presenter: Eberhard Grube

June 07, 2014

Presentation TVT 2014

Postdilation After TAVR: (1) When is it Indicated? (2) Is it Safe? (3) What are the Outcomes?

Presenter: Rebecca T. Hahn

June 07, 2014

Presentation TVT 2014

Why Cerebral Protection after TAVR Will be Used Sparingly (if at all) in the Future

Presenter: Ganesh Manoharan

June 07, 2014

Presentation TVT 2014

Perspectives on Predilation from an Experienced SAPIEN User

Presenter: Raj Makkar

June 07, 2014

Presentation TVT 2014

A Rationale Approach to Adjunct Pharmacotherapy After TAVR (With Stroke in Mind)

Presenter: Susheel Kodali

June 07, 2014

Presentation TVT 2014

Reasons and Results of NO Predilation Before TAVR: How to Improve Outcomes and SIMPLIFY Your Life

Presenter: Mathew Williams

June 07, 2014

Presentation TVT 2014

General Anesthesia is a Liability and TEE is Mostly Unnecessary!

Presenter: Ganesh Manoharan

June 07, 2014

Presentation TVT 2014

Has Stroke Frequency Declined After TAVR?

Presenter: Nicolas M. van Mieghem

June 07, 2014

Presentation TVT 2014

General Anesthesia is Easily Managed and TEE is Helpful in Many Patients

Presenter: E. Murat Tuzcu

June 07, 2014

Presentation TVT 2014

Perspectives from the US CoreValve Trials

Presenter: Jeffrey J. Popma

June 07, 2014

Presentation TVT 2014

An Expensive Luxury Definitely Not Needed

Presenter: Helene Eltchaninoff

June 07, 2014

Presentation TVT 2014

Preferred and Useful (When Available)

Presenter: Mathew Williams

June 07, 2014

Presentation TVT 2014

Perspectives from the PARTNER Trials

Presenter: Susheel Kodali

June 07, 2014

Presentation TVT 2014

Lessons Learned about Frailty and Comorbidities from the US CoreValve Trials

Presenter: Michael J. Reardon

June 07, 2014

Presentation TVT 2014

Incidence, Timing, Predictors (New Onset AF, Postdilatation, etc.), and Clinical Impact

Presenter: Samir R. Kapadia

June 07, 2014

Presentation TVT 2014

Stroke Basics after Cardiovascular Interventions: VARC 2 Definitions, Stroke Severity Assessment, Neuroimaging, and Neurocognitive Function

Presenter: Martin B. Leon

June 07, 2014

Presentation TVT 2014

Case Presentation: Frailty and Comorbidities

Presenter: Jean-Michel Paradis

June 07, 2014

Presentation TVT 2014

Special Lecture: Adjunctive Pharmacotherapy During and After TAVR: BRAVO 3 and Beyond

Presenter: George D. Dangas

June 07, 2014

Presentation TVT 2014

Unusual and Interesting Echocardiographic Findings After TAVR: VSDs, Mitral Valve Injury, Periaortic Hematomas, and Others

Presenter: Rebecca T. Hahn

June 07, 2014

Presentation TVT 2014

PVR Assessments Using Hemodynamics and Aortography: The Dimensionless AR Index and Angiography as Complementary Tools

Presenter: Lutz Buellesfeld

June 07, 2014

Advertisement

Why Cerebral Protection after TAVR Will Become the Standard of Care

Postdilation After TAVR: (1) When is it Indicated? (2) Is it Safe? (3) What are the Outcomes?

Why Cerebral Protection after TAVR Will be Used Sparingly (if at all) in the Future

Perspectives on Predilation from an Experienced SAPIEN User

A Rationale Approach to Adjunct Pharmacotherapy After TAVR (With Stroke in Mind)

Reasons and Results of NO Predilation Before TAVR: How to Improve Outcomes and SIMPLIFY Your Life

General Anesthesia is a Liability and TEE is Mostly Unnecessary!

Has Stroke Frequency Declined After TAVR?

General Anesthesia is Easily Managed and TEE is Helpful in Many Patients

Perspectives from the US CoreValve Trials

An Expensive Luxury Definitely Not Needed

Preferred and Useful (When Available)

Perspectives from the PARTNER Trials

Lessons Learned about Frailty and Comorbidities from the US CoreValve Trials

Incidence, Timing, Predictors (New Onset AF, Postdilatation, etc.), and Clinical Impact

Stroke Basics after Cardiovascular Interventions: VARC 2 Definitions, Stroke Severity Assessment, Neuroimaging, and Neurocognitive Function

Case Presentation: Frailty and Comorbidities

Special Lecture: Adjunctive Pharmacotherapy During and After TAVR: BRAVO 3 and Beyond

Unusual and Interesting Echocardiographic Findings After TAVR: VSDs, Mitral Valve Injury, Periaortic Hematomas, and Others

PVR Assessments Using Hemodynamics and Aortography: The Dimensionless AR Index and Angiography as Complementary Tools

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content